

## **AMENDMENTS TO THE CLAIMS:**

Claims 1–44 are canceled.

45. (Currently Amended) A pharmaceutical preparation comprising a combination of oxycodone and/or its pharmaceutically acceptable salts, and naloxone and/or its pharmaceutically acceptable salts, the combination in a controlled release matrix providing sustained release, wherein the preparation comprises oxycodone and/or its pharmaceutically acceptable salts and naloxone and/or its pharmaceutically acceptable salts in a weight ratio of 2:1, wherein the naloxone and/or its pharmaceutically acceptable salts is present in an amount range of about [5] 1 to about 50 mg and wherein oxycodone and/or its pharmaceutically acceptable salts is present in an amount ranging from about 10 to about [100] 150 mg.

46. (Previously presented) Preparation according to claim 45, wherein the oxycodone or its pharmaceutically acceptable salts is present in an amount ranging from about 10 to about 80 mg.

47. (Previously presented) Preparation according to claim 45, characterized in that oxycodone and naloxone are present in the form of pharmaceutically acceptable and equally active derivatives, such as the free-based salts and the like.

48. (Previously presented) Preparation according to claim 47, characterized in that oxycodone and naloxone are present as hydrochloride, sulfate, bisulfate, tartrate, nitrate, citrate, bitartrate, phosphate, malate, maleate, hydrobromide, hydroiodide, fumarate or succinate.

49. (Previously presented) Preparation according to claim 45, characterized in that the matrix comprises at least ethylcellulose or at least one fatty alcohol as the components that essentially influence the release behavior of the active compounds.

50. (Previously presented) Preparation according to claim 49, characterized in that the fatty alcohols comprise lauryl, myrestyl, stearyl, cetostearyl, ceryl, and/or cetyl alcohol.

51. (Previously presented) Preparation according to claim 50, characterized in that the fatty alcohol is stearyl alcohol.

52. (Previously presented) Preparation according to claim 45, characterized in that the preparation comprises fillers and additional excipients.

53. (Previously presented) Preparation according to claim 52, characterized in that the preparation comprises one or more materials selected from the group consisting of lubricants, flowing agents and plasticizers.

54. (Previously presented) Preparation according to claim 53, characterized in that the preparation comprises one or more lubricants selected from the group consisting of magnesium stearate, calcium stearate, stearic acid, calcium laureate, and fatty acids.

55. (Previously presented) Preparation according to claim 54, characterized in that the preparation comprises stearic acid.

56. (Previously presented) Preparation according to claim 53, characterized in that the preparation comprises a flowing agent selected from the group consisting of highly-dispersed silica, talcum, corn starch, magnesium oxide, magnesium stearate and/or calcium stearate.

57. (Previously presented) Preparation according to claim 45, characterized in that the preparation has been formulated for oral, nasal, rectal application or application by inhalation.

58. (Previously presented) Preparation according to claim 45, characterized in that the preparation is a tablet, pill, capsule, granule and/or powder.